Translational Cancer Epigenomics

Official account Section Translational Cancer Epigenomics @TMO_Heidelberg @NCT_HD @DKFZ, #epigenomics, #hematopoiesis, #JMML, #singleCell, #precisiononcology

[Translational Cancer Epigenomics @TransCanEpi]

🧵 NEW PAPER in @BloodJournal!

Why do IDH1 mutations almost exclusively drive myeloid #leukemia, while IDH2 mutations occur in both myeloid AND lymphoid cancers? #AML #Epigenetics

Despite sharing the same biochemical mechanism, they are NOT equivalent. Here's what we found 👇

[Ofir Cohn @CohnOfir]

Decades of research have revealed the intricacies of how dendritic cells (DCs) function, but fundamental questions remain about how this group of cells develops in humans and how this process goes awry in disease. A thread on our new work! (1/9)
https://t.co/9hgDt3r8n1

[Cancer Chromatin & Epigenetics Club @CancrEpigenetic]

📢Another exciting seminar on CCEC, scheduled on Friday 6thJun@3PM,UKtime with Alvaro Rada Iglesias @IBBTEC Cantabria.
Alvaro will discuss: Enhancer-Promoter contact, a key feature in gene regulation, how and why?? link2join https://t.co/V7gUW5YReJ
@ShuchiChromaBio
@activemotif

[Translational Cancer Epigenomics @TransCanEpi]

13/ Huge congratulations to first author @MariamHakobya20 and all collaborators and a big THANK YOU for all your efforts and support throughout the project! 🎉

📄 Paper link 👇
https://t.co/GN7uwEc74j
#AML #Leukemia #IDH1 #Epigenetics #Hematology #BloodCancer @DKFZ @NCT_HD

[Translational Cancer Epigenomics @TransCanEpi]

🧵 NEW PAPER in @BloodJournal!

Why do IDH1 mutations almost exclusively drive myeloid #leukemia, while IDH2 mutations occur in both myeloid AND lymphoid cancers? #AML #Epigenetics

Despite sharing the same biochemical mechanism, they are NOT equivalent. Here's what we found 👇

[Translational Cancer Epigenomics @TransCanEpi]

12/ To summarise:

→ IDH1 is highly expressed in myeloid progenitors (unlike IDH2)
→ Mutant IDH1 epigenetically silences Cebpe → neutrophil block
→ The block persists after IDH1 inhibition alone
→ IDH1i + hypomethylating agent fully rescues the defect

[Elvin Wagenblast @Elvin_Wag]

Grateful to @JianXuLab for this perspective highlighting how oncogenes, developmental ontogeny, and cellular plasticity intersect in pediatric leukemia, alongside the JMML study by @mp_hartmann and @dblipka1. @BCD_AACR @CD_AACR https://t.co/n9cN5J4hz1

[Mark Hartmann @mp_hartmann]

I can only agree with that!

[Blood Cancer Discovery @BCD_AACR]

Now online: Molecular Plasticity Results in Oncofetal Reprogramming and Therapeutic Vulnerabilities in Juvenile Myelomonocytic Leukemia https://t.co/lsPJPaJLr3

[Michael Kharas MSK @KharasLab]

Check out our latest story https://t.co/7wLiJlYDyy! Huge thanks to @GauravA_UK and the @bloodgenes lab for driving this work forward together with us. This was a great team effort with outstanding collaborators @_ruslansoldatov, @AbdelWahablab, and @AlexBickMDPhD.

[Ankur Sharma @asharmaiisc]

Here, in this @Cancer_Cell mini-review, we highlight recent advances in understanding oncofetal reprogramming and explore its emerging potential as a biomarker and therapeutic target in cancer research. @FGinhoux
https://t.co/Kmq40vqItQ